Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...done (...under observation of 0815ax)
CORPORATE GOVERNANCE
http://finance.yahoo.com/q/pr?s=FITB
Fifth Third Bancorp's Corporate Governance Quotient (CGQ®) as of 1-Apr-09 is better than 96.1% of S&P 500 companies and 100% of Banks companies.
TNL (on my watchlist)
http://shortsqueeze.com/?symbol=tnl&submit=Short+Quote%99
Technitrol Inc. $ 3.27
TNL
Short Interest (Shares Short) 808,900
Days To Cover (Short Interest Ratio) 1.8
Short Percent of Float 2.17 %
Short Interest - Prior 973,100
Short % Increase / Decrease -16.87 %
Short Squeeze Ranking™ -3
% From 52-Wk High ($ 24.66 ) -654.13 %
% From 52-Wk Low ($ 0.95 ) 70.95 %
% From 200-Day MA ($ 3.77 ) -15.29 %
% From 50-Day MA ($ 1.78 ) 45.57 %
Price % Change (52-Week) -87.70 %
Shares Float 37,230,000
Total Shares Outstanding 40,998,413
% Owned by Insiders 9.11 %
% Owned by Institutions 80.20 %
Market Cap. $ 134,064,811
Trading Volume - Today 492,124
Trading Volume - Average 455,700
Trading Volume - Today vs. Average 107.99 %
Earnings Per Share -6.77
PE Ratio
Record Date 2009-AprilA
http://finance.yahoo.com/q/pr?s=TNL
BUSINESS SUMMARY
Technitrol, Inc. produces precision-engineered electronic components, and electrical contact products and materials worldwide. The company operates in two segments, Electronic Components and Electrical Contact Products. The Electronic Components segment designs and manufactures electronic components and modules, such as antennas, speakers, receivers, microphones, switches, chokes, inductors, filters, transformers, and coils. Its products are used for antenna systems for non-cellular wireless and automotive systems; terminal devices, primarily handsets and personal digital assistants (PDAs); audio receivers and amplifiers; broadband access equipment; Ethernet switches; military/aerospace navigation, and weapon guidance systems; power supplies; routers; televisions and DVD players; laptop computers; video game consoles; voice over internet equipment; and automotive drivetrains. This segment serves original equipment manufacturers, original design manufacturers, contract manufacturers, and distributors in various industries, including wireless terminals, such as handsets and PDAs; hearing instruments and other medical devices; consumer electronics; enterprise networking; professional and consumer audio; military/aerospace; power conversion; telecommunications; and automotive. The Electrical Contact Products segment produces an array of precious metal electrical contact products that are used in electrical circuit breakers; motor and temperature control devices; power substations; sensors; switches and relays; telephone and computer equipment; and wiring devices. This segment serves original equipment and design manufacturers in various industries comprising household appliances, automotive, residential and non-residential construction circuitry, commercial and industrial controls, electric power distribution, telecommunications, and consumer electronics. The company was founded in 1947 and is headquartered in Trevose, Pennsylvania.
http://www.mffais.com/tnl
*** (c)LI-portfolio 0815ax (BigBoards) 04/2009 ***
ACAS ANPI APPY CENX CETV CTIC CPE EMKR FITB GNW HIG
KV.A MTG(*) NEXM PLD PWAV RZ STP SRZ XL XTXI YGE
(*) new
*** (c)LI-portfolio 0815ax (OTCBB) 04/2009 ***
GNPH NEOM
MTG -
http://finance.yahoo.com/q/ks?s=MTG
Share Statistics
Average Volume (3 month)3: 4,025,200
Average Volume (10 day)3: 5,303,250
Shares Outstanding5: 124.95M
Float: 123.64M
% Held by Insiders1: 31.52%
% Held by Institutions1: 77.90%
Shares Short (as of 26-Mar-09)3: 24.21M
Short Ratio (as of 26-Mar-09)3: 3.9
Short % of Float (as of 26-Mar-09)3: 19.80%
Shares Short (prior month)3: 20.23M
... (back to MTG chart) -
continues to rise
...hopefully $.20 today!
ANPI ...pre-market $.90 (high: $.94) ...
ANPI ...pre-market $.78 ...
ACAS -
http://ih.advfn.com/p.php?pid=nmona&cb=1239796243&article=37282745&symbol=N^ACAS
Date : 04/14/2009 @ 3:49PM
Source : PR Newswire
American Capital Receives Cash Proceeds of $22 Million from Sale of Corrpro Companies
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- American Capital Ltd. (NASDAQ:ACAS) announced today that in the first quarter of 2009 it received cash proceeds of $22 million from the sale of its portfolio company Corrpro Companies Inc. to a wholly-owned subsidiary of Insituform Technologies Inc. (NASDAQ:INSU), realizing a gain of $6 million. Including investments in Corrpro by American Capital's affiliated funds under management, total inception to date realized gains and dividends received were $9 million. American Capital's compounded annual rate of return, including interest, dividends and fees earned over the life of its investment was 21%. The proceeds received by American Capital were greater than the fourth quarter 2008 valuation of the investment by $0.5 million, or 2%.
In March 2004, American Capital invested $16 million in Corrpro to support its recapitalization by Wingate Partners. American Capital's investment took the form of senior subordinated debt with warrants and redeemable preferred equity with warrants.
"It has been a pleasure to partner with Wingate for the first time on our investment in Corrpro," said Douglas Kelley, Principal, Sponsor Finance Group. "Over the course of our five year investment, Corrpro made strategic investments in marketing and personnel, which were critical in growing revenue and cash flow. We commend management on making the right investments in attractive market segments, which generated attractive returns for all company stakeholders, including American Capital."
Corrpro, headquartered in Medina, Ohio and Houston, Texas, with over 30 offices worldwide, is a leading provider of corrosion control engineering services, systems and equipment to the infrastructure, environmental and energy markets around the world. Corrpro is the leading provider of cathodic protection systems and engineering services, as well as corrosion protection services relating to coatings, pipeline integrity and reinforced concrete structures.
Since American Capital's August 1997 IPO through the fourth quarter of 2008, the company has earned a 17% compounded annual return, including interest, dividends, fees and net gains, on 249 realizations of senior debt, subordinated debt and equity investments, totaling $11 billion of committed capital. These realizations represent 47% of all amounts invested by American Capital since its August 1997 IPO. Proceeds from these realizations exceeded the total associated prior quarter valuation of the investments by less than 1%. American Capital earned a 30% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.
For more information about American Capital's investment in Corrpro, please go to http://www.americancapital.com/news/newsreleases/2004/pr20040331.html.
For a chart showing American Capital's exited portfolio companies, please go to http://www.americancapital.com/our_portfolio/exited.html.
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $14 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to http://www.americancapital.com/.
(1)As of December 31, 2008.
Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.
This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group (214) 273-6655 Jennifer Burke, Corporate Communications (301) 968-9400
DATASOURCE: American Capital Ltd.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group,
+1-214-273-6655, or Jennifer Burke, Corporate Communications of American
Capital Ltd., +1-301-968-9400
Web Site: http://www.americancapital.com/
ACAS -
http://ih.advfn.com/p.php?pid=nmona&cb=1239796243&article=37282745&symbol=N^ACAS
Date : 04/14/2009 @ 3:49PM
Source : PR Newswire
American Capital Receives Cash Proceeds of $22 Million from Sale of Corrpro Companies
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- American Capital Ltd. (NASDAQ:ACAS) announced today that in the first quarter of 2009 it received cash proceeds of $22 million from the sale of its portfolio company Corrpro Companies Inc. to a wholly-owned subsidiary of Insituform Technologies Inc. (NASDAQ:INSU), realizing a gain of $6 million. Including investments in Corrpro by American Capital's affiliated funds under management, total inception to date realized gains and dividends received were $9 million. American Capital's compounded annual rate of return, including interest, dividends and fees earned over the life of its investment was 21%. The proceeds received by American Capital were greater than the fourth quarter 2008 valuation of the investment by $0.5 million, or 2%.
In March 2004, American Capital invested $16 million in Corrpro to support its recapitalization by Wingate Partners. American Capital's investment took the form of senior subordinated debt with warrants and redeemable preferred equity with warrants.
"It has been a pleasure to partner with Wingate for the first time on our investment in Corrpro," said Douglas Kelley, Principal, Sponsor Finance Group. "Over the course of our five year investment, Corrpro made strategic investments in marketing and personnel, which were critical in growing revenue and cash flow. We commend management on making the right investments in attractive market segments, which generated attractive returns for all company stakeholders, including American Capital."
Corrpro, headquartered in Medina, Ohio and Houston, Texas, with over 30 offices worldwide, is a leading provider of corrosion control engineering services, systems and equipment to the infrastructure, environmental and energy markets around the world. Corrpro is the leading provider of cathodic protection systems and engineering services, as well as corrosion protection services relating to coatings, pipeline integrity and reinforced concrete structures.
Since American Capital's August 1997 IPO through the fourth quarter of 2008, the company has earned a 17% compounded annual return, including interest, dividends, fees and net gains, on 249 realizations of senior debt, subordinated debt and equity investments, totaling $11 billion of committed capital. These realizations represent 47% of all amounts invested by American Capital since its August 1997 IPO. Proceeds from these realizations exceeded the total associated prior quarter valuation of the investments by less than 1%. American Capital earned a 30% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.
For more information about American Capital's investment in Corrpro, please go to http://www.americancapital.com/news/newsreleases/2004/pr20040331.html.
For a chart showing American Capital's exited portfolio companies, please go to http://www.americancapital.com/our_portfolio/exited.html.
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $14 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to http://www.americancapital.com/.
(1)As of December 31, 2008.
Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.
This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group (214) 273-6655 Jennifer Burke, Corporate Communications (301) 968-9400
DATASOURCE: American Capital Ltd.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group,
+1-214-273-6655, or Jennifer Burke, Corporate Communications of American
Capital Ltd., +1-301-968-9400
Web Site: http://www.americancapital.com/
ANPI -
http://ih.advfn.com/p.php?pid=nmona&cb=1239796243&article=37284807&symbol=N^ANPI
Date : 04/14/2009 @ 8:30PM
Source : PR Newswire
Angiotech Pharmaceuticals, Inc. - New study shows that Zilver(R) PTX(TM) effectively treats blockages in critical thigh artery
VANCOUVER, April 14 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today announced its corporate partner, Cook Medical, reported data on two-year follow up that showed that 82 percent of patients who were treated with Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent (DES) were free from reintervention at two-year follow up. The Zilver PTX Registry study, involving 792 patients from across the world, is assessing the safety and efficacy of the Zilver PTX in treating PAD. The most recent results were reported at the 31st International Symposium: Charing Cross Controversies Challenges Consensus.
"These results are extremely encouraging as it's the first time paclitaxel-coated stents have been used in the treatment of blockages in arteries outside the heart," said Zilver PTX global principal investigator, Dr. Michael Dake, Professor in the Department of Cardiothoracic Surgery at Stanford University Medical School and Medical Director of the Cath/Angio Laboratories at Stanford University Medical Center. "Patients treated with the Zilver PTX had a very low complication rate and required fewer reinterventions."
Data was compiled at 12 and 24 months for 593 patients and 177 patients respectively from the registry study, which enrolled a broad spectrum of patients, including those with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding event-free survival (EFS) rates were 87 percent and 78 percent, and freedom from TLR (target lesion revascularization) was 89 percent and 82 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six and 12 months and were maintained through 24 months.
Detailed evaluation of stent x-rays demonstrated excellent stent integrity through 12 months, confirming previously published results showing 99 percent completely intact stents with a mean follow up of 2.4 years in the challenging superior femoral artery and popliteal arteries, including behind the knee locations.
One in five in the 65- to 75-year-old age group in the UK* has peripheral arterial disease (PAD). Yet only a quarter of these people have any symptoms at all. The 'silent' nature of this condition can result in a number of patients being diagnosed only when their condition has progressed to the severe stage. In patients with severe PAD whose condition is not improving with risk-factor modification, exercise programs and pharmacological therapy, invasive procedures may need to be carried out. These procedures include angioplasty, stenting or surgery.
"We are impressed with both the efficacy and durability demonstrated by the Zilver PTX in the registry study and believe we will see similar results in the US randomized trial which is currently ongoing," said Dr. Bill Hunter, President and CEO of Angiotech. "Our partner, Cook Medical, has been committed to continually improving the efficacy and safety of peripheral DES and early results suggest that the self-expanding, Zilver PTX stent will be an important treatment option for patients with PAD."
In addition to the registry arm of the study, the 480 patient randomized component is designed to evaluate the Zilver PTX across 45 trial sites in the United States, Japan and Europe. Of the 480 patients enrolled in the randomized study, 240 received the Zilver PTX DES. Enrollment in the randomized study was completed in 2008. For more information, please visit http://www.zilverptxtrial.com/.
* Fowkes FGR, Housley E, Cawood EHH, MacIntyre CAA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-91.
Cook licenses the rights to use paclitaxel with peripheral stents and other non-coronary medical devices from Angiotech. Under the terms of its 1997 license agreement with Cook, Angiotech is entitled to ereceive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular products, including the Zilver PTX.
Forward Looking Statements --------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at http://www.angiotech.com/.
DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: DeDe Sheel, Investor Relations and Corporate Communications,
Angiotech Pharmaceuticals, Inc., (415) 293-4412,
ANPI (04/14: $0.467) -
http://ih.advfn.com/p.php?pid=nmona&cb=1239796243&article=37284807&symbol=N^ANPI
Date : 04/14/2009 @ 8:30PM
Source : PR Newswire
Angiotech Pharmaceuticals, Inc. - New study shows that Zilver(R) PTX(TM) effectively treats blockages in critical thigh artery
VANCOUVER, April 14 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today announced its corporate partner, Cook Medical, reported data on two-year follow up that showed that 82 percent of patients who were treated with Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent (DES) were free from reintervention at two-year follow up. The Zilver PTX Registry study, involving 792 patients from across the world, is assessing the safety and efficacy of the Zilver PTX in treating PAD. The most recent results were reported at the 31st International Symposium: Charing Cross Controversies Challenges Consensus.
"These results are extremely encouraging as it's the first time paclitaxel-coated stents have been used in the treatment of blockages in arteries outside the heart," said Zilver PTX global principal investigator, Dr. Michael Dake, Professor in the Department of Cardiothoracic Surgery at Stanford University Medical School and Medical Director of the Cath/Angio Laboratories at Stanford University Medical Center. "Patients treated with the Zilver PTX had a very low complication rate and required fewer reinterventions."
Data was compiled at 12 and 24 months for 593 patients and 177 patients respectively from the registry study, which enrolled a broad spectrum of patients, including those with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding event-free survival (EFS) rates were 87 percent and 78 percent, and freedom from TLR (target lesion revascularization) was 89 percent and 82 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six and 12 months and were maintained through 24 months.
Detailed evaluation of stent x-rays demonstrated excellent stent integrity through 12 months, confirming previously published results showing 99 percent completely intact stents with a mean follow up of 2.4 years in the challenging superior femoral artery and popliteal arteries, including behind the knee locations.
One in five in the 65- to 75-year-old age group in the UK* has peripheral arterial disease (PAD). Yet only a quarter of these people have any symptoms at all. The 'silent' nature of this condition can result in a number of patients being diagnosed only when their condition has progressed to the severe stage. In patients with severe PAD whose condition is not improving with risk-factor modification, exercise programs and pharmacological therapy, invasive procedures may need to be carried out. These procedures include angioplasty, stenting or surgery.
"We are impressed with both the efficacy and durability demonstrated by the Zilver PTX in the registry study and believe we will see similar results in the US randomized trial which is currently ongoing," said Dr. Bill Hunter, President and CEO of Angiotech. "Our partner, Cook Medical, has been committed to continually improving the efficacy and safety of peripheral DES and early results suggest that the self-expanding, Zilver PTX stent will be an important treatment option for patients with PAD."
In addition to the registry arm of the study, the 480 patient randomized component is designed to evaluate the Zilver PTX across 45 trial sites in the United States, Japan and Europe. Of the 480 patients enrolled in the randomized study, 240 received the Zilver PTX DES. Enrollment in the randomized study was completed in 2008. For more information, please visit http://www.zilverptxtrial.com/.
* Fowkes FGR, Housley E, Cawood EHH, MacIntyre CAA, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-91.
Cook licenses the rights to use paclitaxel with peripheral stents and other non-coronary medical devices from Angiotech. Under the terms of its 1997 license agreement with Cook, Angiotech is entitled to ereceive royalty payments upon the commercial sale of paclitaxel-eluting peripheral vascular products, including the Zilver PTX.
Forward Looking Statements --------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at http://www.angiotech.com/.
DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: DeDe Sheel, Investor Relations and Corporate Communications,
Angiotech Pharmaceuticals, Inc., (415) 293-4412,
...are on the way in Easter vacation
==> later
...dito!
I have to wait until $4 (then will make the 40/60-splitting)
gooooo.....
RZ to Unveil 100 mpg SUV at SAE World Congress in Detroit
http://ih.advfn.com/p.php?pid=nmona&cb=1239295061&article=37227450&symbol=NY^RZ
Raser to Unveil 100 mpg SUV at SAE World Congress in Detroit
Raser Technologies, Inc. (NYSE:RZ) announced today it will unveil a 100+ mpg SUV at the Society of Automotive Engineers (SAE) World Congress in Detroit, Michigan April 20-23, 2009. The Vehicle is powered by Raser’s E-REV powertrain and was developed in conjunction with Raser’s integration partner, FEV and a global automaker. The full-size SUV is a four-wheel drive Extended-Range Electric Vehicle (E-REV) designed to achieve over 100 mpg in typical local daily driving with near zero emissions by driving up to 40 miles per day in all-electric mode.
Just one year ago, at the SAE World Congress, Raser announced it was developing an E-REV powertrain for use in full size SUVs and light trucks and had teamed with a leading OEM to build a demonstration SUV. This highly anticipated vehicle, featuring Raser’s electric powertrain, is now in road testing and will be unveiled and on display at this year’s show in FEV’s booth. In addition to SUVs, the powertrain is sized for application in many popular light trucks.
The SAE World Congress is the largest annual gathering of automotive engineers and typically highlights innovative automotive developments that often are incorporated in future production vehicles. The four-day Congress in Detroit is expected to host over 30,000 industry specialists, engineers and business leaders.
“We are excited to be able to demonstrate an electric powertrain for larger vehicles such as trucks and SUVs,” said James Spellman, Vice President, of Transportation for Raser Technologies. “These are the best selling vehicles in America and can benefit the most from increased fuel economy and reduced emissions. We are also pleased to be exhibiting with our development partner FEV.”
“We are pleased to support Raser in the development of this exciting project. Our goal in exhibiting this breakthrough vehicle is to demonstrate that electric vehicle technology is a viable solution for a variety of vehicle platforms,” said Gary Rogers, president and CEO of FEV. “Needs of consumers will continue to vary, and this full-sized SUV range-extended electric vehicle shows that fuel economy does not necessarily mean sacrificing power and utility.”
About Raser Technologies
Raser (NYSE:RZ) is an environmental Energy Technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial segment. Raser’s Transportation & Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
About FEV, Inc.
The FEV Group is an internationally recognized powertrain and vehicle engineering company that supplies the global transportation industry. FEV offers a complete range of engineering services, providing support across the globe to customers in the design, analysis, prototyping, powertrain and transmission development, as well as vehicle integration, calibration and homologation for advanced internal combustion gasoline-, diesel-, and alternative-fueled powertrains. FEV also designs, develops and prototypes advanced vehicle / powertrain electronic control systems and hybrid-electric engine concepts that address future emission and fuel economy standards. The FEV Test Systems division is a global supplier of advanced test cell, instrumentation and test equipment. The FEV Group employs a staff of over 1,800 highly skilled specialists at advanced technical centers on three continents. FEV, Inc. employs approximately 300 personnel at FEV’s North American Technical Center in Auburn Hills, MI.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the performance and market applicability of our products; our beliefs about the status and enforceability of the Company's intellectual property; our beliefs about the strength of our existing and potential business relations in the motor industry; our beliefs about the strength and enforceability of our agreements, our beliefs about the performance capabilities of our technology; our beliefs about the capabilities, expertise and intentions of our partners; our ability to hire, train and retain key personnel; our ability to successfully complete field testing of Symetron™ technologies. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; the strength of our intellectual property; our inability to attract, train and retain key personnel; and such other risks as identified in our annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
RZ to Unveil 100 mpg SUV at SAE World Congress in Detroit
http://ih.advfn.com/p.php?pid=nmona&cb=1239295061&article=37227450&symbol=NY^RZ
Raser to Unveil 100 mpg SUV at SAE World Congress in Detroit
Date : 04/08/2009 @ 9:02AM
Raser Technologies, Inc. (NYSE:RZ) announced today it will unveil a 100+ mpg SUV at the Society of Automotive Engineers (SAE) World Congress in Detroit, Michigan April 20-23, 2009. The Vehicle is powered by Raser’s E-REV powertrain and was developed in conjunction with Raser’s integration partner, FEV and a global automaker. The full-size SUV is a four-wheel drive Extended-Range Electric Vehicle (E-REV) designed to achieve over 100 mpg in typical local daily driving with near zero emissions by driving up to 40 miles per day in all-electric mode.
Just one year ago, at the SAE World Congress, Raser announced it was developing an E-REV powertrain for use in full size SUVs and light trucks and had teamed with a leading OEM to build a demonstration SUV. This highly anticipated vehicle, featuring Raser’s electric powertrain, is now in road testing and will be unveiled and on display at this year’s show in FEV’s booth. In addition to SUVs, the powertrain is sized for application in many popular light trucks.
The SAE World Congress is the largest annual gathering of automotive engineers and typically highlights innovative automotive developments that often are incorporated in future production vehicles. The four-day Congress in Detroit is expected to host over 30,000 industry specialists, engineers and business leaders.
“We are excited to be able to demonstrate an electric powertrain for larger vehicles such as trucks and SUVs,” said James Spellman, Vice President, of Transportation for Raser Technologies. “These are the best selling vehicles in America and can benefit the most from increased fuel economy and reduced emissions. We are also pleased to be exhibiting with our development partner FEV.”
“We are pleased to support Raser in the development of this exciting project. Our goal in exhibiting this breakthrough vehicle is to demonstrate that electric vehicle technology is a viable solution for a variety of vehicle platforms,” said Gary Rogers, president and CEO of FEV. “Needs of consumers will continue to vary, and this full-sized SUV range-extended electric vehicle shows that fuel economy does not necessarily mean sacrificing power and utility.”
About Raser Technologies
Raser (NYSE:RZ) is an environmental Energy Technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial segment. Raser’s Transportation & Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
About FEV, Inc.
The FEV Group is an internationally recognized powertrain and vehicle engineering company that supplies the global transportation industry. FEV offers a complete range of engineering services, providing support across the globe to customers in the design, analysis, prototyping, powertrain and transmission development, as well as vehicle integration, calibration and homologation for advanced internal combustion gasoline-, diesel-, and alternative-fueled powertrains. FEV also designs, develops and prototypes advanced vehicle / powertrain electronic control systems and hybrid-electric engine concepts that address future emission and fuel economy standards. The FEV Test Systems division is a global supplier of advanced test cell, instrumentation and test equipment. The FEV Group employs a staff of over 1,800 highly skilled specialists at advanced technical centers on three continents. FEV, Inc. employs approximately 300 personnel at FEV’s North American Technical Center in Auburn Hills, MI.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the performance and market applicability of our products; our beliefs about the status and enforceability of the Company's intellectual property; our beliefs about the strength of our existing and potential business relations in the motor industry; our beliefs about the strength and enforceability of our agreements, our beliefs about the performance capabilities of our technology; our beliefs about the capabilities, expertise and intentions of our partners; our ability to hire, train and retain key personnel; our ability to successfully complete field testing of Symetron™ technologies. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; the strength of our intellectual property; our inability to attract, train and retain key personnel; and such other risks as identified in our annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
RZ to Unveil 100 mpg SUV at SAE World Congress in Detroit
http://ih.advfn.com/p.php?pid=nmona&cb=1239295061&article=37227450&symbol=NY^RZ
Raser to Unveil 100 mpg SUV at SAE World Congress in Detroit
Raser Technologies, Inc. (NYSE:RZ) announced today it will unveil a 100+ mpg SUV at the Society of Automotive Engineers (SAE) World Congress in Detroit, Michigan April 20-23, 2009. The Vehicle is powered by Raser’s E-REV powertrain and was developed in conjunction with Raser’s integration partner, FEV and a global automaker. The full-size SUV is a four-wheel drive Extended-Range Electric Vehicle (E-REV) designed to achieve over 100 mpg in typical local daily driving with near zero emissions by driving up to 40 miles per day in all-electric mode.
Just one year ago, at the SAE World Congress, Raser announced it was developing an E-REV powertrain for use in full size SUVs and light trucks and had teamed with a leading OEM to build a demonstration SUV. This highly anticipated vehicle, featuring Raser’s electric powertrain, is now in road testing and will be unveiled and on display at this year’s show in FEV’s booth. In addition to SUVs, the powertrain is sized for application in many popular light trucks.
The SAE World Congress is the largest annual gathering of automotive engineers and typically highlights innovative automotive developments that often are incorporated in future production vehicles. The four-day Congress in Detroit is expected to host over 30,000 industry specialists, engineers and business leaders.
“We are excited to be able to demonstrate an electric powertrain for larger vehicles such as trucks and SUVs,” said James Spellman, Vice President, of Transportation for Raser Technologies. “These are the best selling vehicles in America and can benefit the most from increased fuel economy and reduced emissions. We are also pleased to be exhibiting with our development partner FEV.”
“We are pleased to support Raser in the development of this exciting project. Our goal in exhibiting this breakthrough vehicle is to demonstrate that electric vehicle technology is a viable solution for a variety of vehicle platforms,” said Gary Rogers, president and CEO of FEV. “Needs of consumers will continue to vary, and this full-sized SUV range-extended electric vehicle shows that fuel economy does not necessarily mean sacrificing power and utility.”
About Raser Technologies
Raser (NYSE:RZ) is an environmental Energy Technology company focused on geothermal power development and technology licensing. Raser’s Power Systems segment is seeking to develop clean, renewable geothermal electric power plants and bottom-cycling operations, incorporating licensed heat transfer technology and Raser’s Symetron™ technology developed internally by its Transportation and Industrial segment. Raser’s Transportation & Industrial segment focuses on extended-range plug-in-hybrid vehicle solutions and using Raser’s award-winning Symetron™ technology to improve the torque density and efficiency of the electric motors and drive systems used in electric and hybrid-electric vehicle powertrains and industrial applications. Further information on Raser may be found at: www.rasertech.com.
About FEV, Inc.
The FEV Group is an internationally recognized powertrain and vehicle engineering company that supplies the global transportation industry. FEV offers a complete range of engineering services, providing support across the globe to customers in the design, analysis, prototyping, powertrain and transmission development, as well as vehicle integration, calibration and homologation for advanced internal combustion gasoline-, diesel-, and alternative-fueled powertrains. FEV also designs, develops and prototypes advanced vehicle / powertrain electronic control systems and hybrid-electric engine concepts that address future emission and fuel economy standards. The FEV Test Systems division is a global supplier of advanced test cell, instrumentation and test equipment. The FEV Group employs a staff of over 1,800 highly skilled specialists at advanced technical centers on three continents. FEV, Inc. employs approximately 300 personnel at FEV’s North American Technical Center in Auburn Hills, MI.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding: our beliefs about the performance and market applicability of our products; our beliefs about the status and enforceability of the Company's intellectual property; our beliefs about the strength of our existing and potential business relations in the motor industry; our beliefs about the strength and enforceability of our agreements, our beliefs about the performance capabilities of our technology; our beliefs about the capabilities, expertise and intentions of our partners; our ability to hire, train and retain key personnel; our ability to successfully complete field testing of Symetron™ technologies. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the competitive environment and our ability to compete in the industry; the strength of our intellectual property; our inability to attract, train and retain key personnel; and such other risks as identified in our annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and all subsequent filings. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
... (first / second ) -
nobody is all-knowing!
but today it is better not to be “short”
http://www.thestreet.com/_yahoo/story/10484482/1/financial-winners-and-losers-wells-fargo.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
...is MTG - not MGM
?? MTG -
http://shortsqueeze.com/?symbol=mtg&submit=Short+Quote%99
Short Interest (Shares Short) 20,229,500
Days To Cover (Short Interest Ratio) 2.8
Short Percent of Float 16.32 %
http://finance.yahoo.com/q/ks?s=MTG
Balance Sheet
Total Cash (mrq): 1.10B
Total Cash Per Share (mrq): 8.782
Total Debt (mrq): 1.07B
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 0.722
Book Value Per Share (mrq): 18.927
Share Statistics
Average Volume (3 month)3: 3,699,100
Average Volume (10 day)3: 2,747,110
Shares Outstanding5: 124.95M
Float: 123.97M
% Held by Insiders1: 31.52%
% Held by Institutions1: 77.90%
Shares Short (as of 10-Mar-09)3: 20.23M
Short Ratio (as of 10-Mar-09)3: 5.2
Short % of Float (as of 10-Mar-09)3: 16.50%
Shares Short (prior month)3: 17.75M>
why "short"
...your own words: 4-6 end of april
...on the way
GNPH
...well analyzes (imo)
German stock ( bottom ~ €3.50 ) Jenoptik
KV Pharmaceutical (NYSE)
http://biz.yahoo.com/ap/090302/kv_pharma_fda.html?.v=1
KV Pharma says it reached manufacturing agreement
http://finance.yahoo.com/news/KV-Pharmaceutical-Enters-Into-prnews-14509433.html
KV Pharmaceutical Enters Into Consent Decree With FDA
"green" since $0.02 (bought October 2007)
still 4 hours opened!
http://www.ariva.de/quote/simple.m?secu=1021
which influence does this news have on pps (this week)?
will NEOM see $0.05 - $0.10 this week?
China Rising Investment Conference (May 18, 2009)
http://www.chinarisingconference.com/presenting.html
The global market meltdown has created opportunities to invest in outstanding companies in what continues to be the fastest growing major economy in the world at historically unprecedented valuations.
Please join the China Rising Investment Conference to meet with the senior management of a wide range of growth companies from China in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy.
Hear the top picks by the best informed analysts currently following Chinese equities. And get in-depth advice on successful China investing strategies from leading public and private equity investors active in China.
30 companies, from microcap to large cap
250 fund managers and investors
Presentations and one-on-one meetings
Analyst roundtable with top picks for 2009
Conference attendance is by invitation only.
Contact Info:
For investment professionals who are interested in attending the conference, please click here to register. We will process your request and get back to you with confirmation.
For individual investors, you are welcome to sign up to listen to webcast.
For company executives who are interested in presenting at the conference, please contact: Crocker Coulson (646) 213 1915 crocker.coulson@ccgir.com
For sponsorship opportunities, please contact Crocker Coulson (646) 213 1915 crocker.coulson@ccgir.com or Karen Ji (310) 954 1351 karen.ji@ccgir.com
Confirmed Presenting Companies:
...
Genesis Pharmaceuticals GNPH